Status: Not yet recruiting
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.
Participants needed: 486
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Zhujiang HospitalUpdated: Jul 28, 2025
Eligibility criteria
Male or non-pregnant women with acute stroke symptoms aged over 18 years. [+4]
Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment. [+24]